Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future. This story matters for Finance & Markets readers tracking fund. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. FundNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily fund signal